RT Journal Article
SR Electronic
T1 Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1786
OP 1792
DO 10.2967/jnumed.122.264205
VO 63
IS 12
A1 Christian Schmidkonz
A1 Torsten Kuwert
A1 Armin Atzinger
A1 Michael Cordes
A1 Georg Schett
A1 Andreas Ramming
A1 Theresa Götz
YR 2022
UL http://jnm.snmjournals.org/content/63/12/1786.abstract
AB Fibroblast activation protein-α (FAP-α) is a type II transmembrane glycoprotein that is overexpressed in activated fibroblasts such as those in the stroma of tumors or in the fibrotic processes accompanying various benign diseases. The recent development and clinical implementation of radiolabeled quinolone-based tracers suitable for PET that act as FAP inhibitors (FAPIs) have opened a new perspective in molecular imaging. Although multiple studies have investigated the use of FAPI imaging in cancer, evidence concerning its use in nonmalignant diseases is still scarce. Herein, we provide a comprehensive review of FAPI imaging in nonmalignant diseases to clarify the current and potential role of this class of molecules in nuclear medicine.